Personalized cancer vaccine plus immunotherapy reduces melanoma recurrence after surgery
Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase 3 INTerpath-001 trial presented at the ESMO Congress 2026. The vaccine, intismeran autogene, was given alongside pembrolizumab and compared with pembrolizumab alone.
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
Want to lose weight? Don't skip the weights
United Kingdom
-
Large meta-analysis sheds new light on how SGLT2 inhibitors affect blood and iron parameters
United Kingdom
-
Airborne ESKAPE pathogens at inner-city clinic resist advanced antibiotics
United Kingdom
-
Shared framework aims to redefine heart health for girls and women
United Kingdom
-
Rare gene variants linked to dental differences that shape our smiles
United Kingdom
-
Small deep brain structure may play major role in sustaining working memory, mouse experiments suggest
United Kingdom
-
Patients given apalutamide and hormone therapy around surgery may cut their risk of metastasis or death
United Kingdom
-
How daylight saving time changes affect you and what you can do about it
United Kingdom